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Abstract
Background—There exists great heterogeneity in patient survival and the time interval between 
motor symptom and dementia onset (MDI) across Lewy body spectrum disorders (LBSD). The 
goal of this study is to identify genetic and pathological findings that have the strongest 
association with these features of clinical heterogeneity in LBSD.
Methods—In this retrospective study, we examined symptom onset, and genetic and 
neuropathological data from a cohort of LBSD patients with autopsy-confirmed α-
synucleinopathy (as of Oct 1, 2015) recruited from 5 clinical research centres in 5 cities in the 
USA. Using histopathology techniques and markers, we assessed the burden of tau neurofibrillary 
tangles, neuritic plaques, α-synuclein inclusions, and other pathologic changes in cortical regions 
using averaged ordinal scores and genotyped cases for variants associated with LBSD. We 
evaluated the time interval from onset of motor symptoms to dementia (MDI) and overall survival 
in groups with varying levels of co-morbid Alzheimer’s disease pathology (AD) according to 
current National Institute on Aging–Alzheimer’s Association neuropathological criteria and used 
multivariate regression to control for age at death and gender.
Findings—This study included 213 patients who had been followed to autopsy and met inclusion 
criteria of clinical LBSD with autopsy-confirmed α-synculeinopathy. Patient groups were 
characterized by no (n=49,23%), low-level (n=56,26%), intermediate-level (n=45,21%) or high-
level (n=63,30%) AD neuropathology. Across groups of increasing levels of AD neuropathology, 
there were higher cerebral α-synuclein scores, shorter MDI, and shorter disease duration 
(p<0·0001 all). Multivariate regression found independent negative associations of cerebral tau 
score with MDI (β= −4·0, 95% CI −5·5 to −2·6; p<0·0001) (R2=0·22, p<0·0001) and with survival 
(β=−2·0, 95% CI −3·2 to −0·8; p<0·0001) (R2=0·15, p<0·0001) in models including age at death, 
gender, cerebral neuritic plaque scores, cerebral α-synuclein, presence of cerebrovascular disease, 
MAPT haplotype, and APOE genotype as covariates.
Interpretation—AD neuropathology is common in LBSD and confers a worse prognosis for 
each increasing level of neuropathological change. Cerebral neurofibrillary tau tangle burden, α-
synuclein pathology, and amyloid plaque pathology are the strongest pathological predictors of a 
shorter MDI and survival in LBSD. In the future, clinical diagnostic criteria which use reliable 
biomarkers for AD neuropathology in LBSD should help identify the most appropriate patients for 
clinical trials of emerging therapies targeting tau, amyloid-beta or α-synuclein, and stratify them 
by level of AD neuropathology.
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Introduction
Parkinson’s disease dementia (PDD)1 and dementia with Lewy bodies (DLB)2 are 
considered to be on a spectrum of clinical manifestations of underlying Lewy body disease3 
characterized by intra-neuronal inclusions composed of pathological α-synuclein (SYN) 
protein (i.e. synucleinopathies)4. The majority of patients with idiopathic Parkinson’s 
disease (PD) will eventually develop dementia over the course of their illness5. However, the 
timing of the onset of dementia is highly variable, with some patients showing no signs of 
cognitive impairment for many years after the onset of PD6–8. In contrast, up to 25% of de 
novo PD patients have mild cognitive impairment (MCI), and incident MCI in patients with 
established PD can rapidly progress to PDD9. Furthermore, according to current consensus 
criteria2, patients with DLB have dementia that precedes or occurs within one year after the 
onset of motor signs of parkinsonism. Although PDD and DLB are diagnostically 
categorized by the timing of symptom occurrence, the clinical features of cognitive and 
motor impairment are often indistinguishable, especially later in disease course1–3. While 
the underlying neuropathological and genetic influences on this variable expression of 
cognitive impairment across Lewy body spectrum disorders (LBSD) are currently unknown, 
we previously found that cortical SYN pathology was the strongest predictor of dementia in 
PD and PDD6. Moreover, patients with a clinical diagnosis of PDD who had significant 
Alzheimer’s disease neuropathology (AD) had a shorter time interval from the onset of PD 
to the onset of dementia, and thus, more closely resembled the natural history of DLB6.
Here we test the hypothesis that co-morbid AD neuropathology (i.e. neuritic plaques, [NPs] 
and neurofibrillary tangles [NFTs]) associates with of the timing of the onset of dementia 
and of survival in LBSD.
Methods
Participants
Patients were recruited by local clinicians and study investigators as part of several pre-
existing clinical research program projects from clinical research centres associated with the 
Udall Center for Excellence in Parkinson’s Disease Research at the University of 
Pennsylvania (Pennsylvania Parkinson’s Disease & Movement Disorders Center, 
Philadelphia VA Medical Center, Alzheimer’s Disease Core Center, or Frontotemporal 
Degeneration Center), the Pacific Northwest Udall Center (University of Washington [UW], 
Seattle, WA, USA) and Oregon Health & Science University ([OHSU] Portland, OR, USA), 
or clinical research centers associated with the Alzheimer’s Disease Research Centers at 
UW, OHSU, the University of Pittsburgh, or Sanders-Brown Center on Aging at the 
University of Kentucky.
Patients who had been followed to autopsy at the corresponding institutional neuropathology 
lab as of October 1, 2015 were included if they met formal clinical criteria for either 
probable DLB2 or PDD10, as previously described,6 with autopsy confirmation of brainstem, 
transitional, or neocortical stage LBSD synucleinopathy2,4. One patient had a secondary 
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neuropathological diagnosis of progressive supranuclear palsy tauopathy which confounds 
the examination of cortical AD tau pathology, and was thus excluded. A subset of 
neuropathological and genetic data presented here (from 103 individuals) were previously 
reported in a smaller cohort of patients in a different analysis of PDD6 or the frequency of 
genetic variants in LBSD11,12 compared with controls. All procedures were performed in 
accordance with local Institutional Review Board guidelines and approvals at each center, 
including written informed consent for autopsy and analysis of tissue sample data. Please 
see supplemental methods for further details on clinical data collection and referral centers.
Procedures
Neuropathological examination was performed (EBL, JQT, JBL, TJM, CDK, RW, JK, PTN) 
using standard methods and the same consensus diagnostic criteria at each center4,13. As 
part of this assessment, sections for each of 7 standardly sampled cortical/limbic regions 
were stained using accepted methods4,13 and graded on an 0–3 ordinal scale4 for NFTs, 
cored or neuritic plaques, and SYN pathology. Please see supplemental methods for further 
details on the methods of staining at each center and other pathological variables. The 
average cerebral score for each pathological change was calculated as previously described6. 
Briefly, an average of the 0–3 ordinal score ratings from these regions were used as a 
continuous measure of cortical pathology burden for NFTs, NPs and SYN (i.e. cerebral 
score). We used Braak neurofibrillary tangle stage and CERAD neuritic plaque score to 
classify AD neuropathology into four groups: no AD neuropathology; “low-level” AD; 
“intermediate-level” AD; and “high-level” AD using modified criteria (supplemental 
methods)4,13. We also dichotomized the burden of AD neuropathology into SYN+AD 
(intermediate/high AD) and SYN−AD (no/low AD) groups, as described previously6 to test 
the diagnostic accuracy of the MDI for detecting SYN+AD.
DNA was isolated from peripheral blood or frozen brain samples using standard 
techniques,6 and samples from individuals were genotyped for common single nucleotide 
polymorphisms (SNPs) in genes previously associated with LBSD11,14—apolipoprotein E 
(APOE ε2, ε3, and ε4 via rs429358/rs7412), tau (MAPT H1 haplotype via risk allele “A” at 
rs1800547) and α-synuclein (SNCA risk allele “G” at rs356219) —by TaqMan assay (Life 
Technologies, Waltham, MA, USA). In addition, the entire glucocerebrosidase gene (GBA) 
coding region and all intron-exon boundaries were sequenced using PCR to detect known 
pathogenic mutations and the coding SNP p.E326K risk allele “G” at rs2230288 as 
described15. Missing data from cases with no or insufficient DNA samples were omitted 
from analysis. All genotyping was performed (CPZ) at the Pacific Northwest Udall Center 
(Seattle, WA, USA).
Statistical Analyses
Continuous variables were analyzed using parametric or non-parametric univariate tests as 
appropriate and categorical variables compared using a chi-square test analysis. Missing data 
was excluded from analyses. To test the diagnostic accuracy of using MDI cut-off of ≤ 1 
year2 to distinguish DLB from PDD, we used receiver-operating characteristic (ROC) curve 
analyses for advanced SYN pathology (neocortical stage vs brainstem or limbic stages) or 
AD pathology (SYN+AD vs SYN−AD) patient groups. Correlations of cerebral NFT, NP, 
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and SYN scores with clinical features (age at death, MDI, and survival) was performed 
using a Spearman correlation.
We used multivariate linear regression to test the independent associations of AD-related 
pathology (i.e. cerebral NFTs and NPs) with the dependent variables MDI and survival. 
Final models were derived from base models controlling for age at death and gender using 
Bayesian Information Criteria16. In the absence of an external validation sample, the final 
model was validated using a bootstrap procedure (i.e. internal validation)17. We report 
average beta estimates with 95% confidence intervals (95% CI) from a bootstrapping 
random sampling procedure with 1,000 bootstrap samples. (Please see Supplementary 
methods for further details on model building procedure).
All analyses were 2-tailed (α=0·05). We adjusted correlation analyses to α=0·003 to correct 
for multiple comparisons and reduce the likelihood of false positive discovery, and 
performed using SPSS v23.0 (IBM, Chicago, IL, USA) or STATA v12.1 (StataCorp, College 
Station, TX, US).
Role of the funding source
The funder of the study had no role in study design, data collection/analysis/interpretation, 
or writing of the report. All authors had full access to all the data in the study and had final 
responsibility for the decision to submit for publication
Results
213 LBSD patients meeting clinical criteria for PDD or DLB who had been followed to 
autopsy by October 1, 2015 at 5 clinical research centres in 5 cities in the USA were 
selected for this study. Two patients were missing survival data and 27 patients were missing 
MDI data. Missing individual neuropathological and genetic variable data are listed in 
Tables 1–2.
Classification of LBSD cases based on stages of AD neuropathology4,13 revealed the 
following distribution (Table 1): 49 patients (23%) had negligible levels of AD 
neuropathological change, i.e. No-AD); 56 patients (26%) had low-level AD; 45 patients 
(21%) had intermediate-level AD; and 63 (30%) had high-level AD. As defined above, there 
were increasing stages of NFT and NP pathology across groups with increasing levels of AD 
neuropathology, including higher NFT/NP cerebral scores (p<0·0001 both), CAA scores 
(p<0·0001), and NFT/NP scores in the basal ganglia (BG) (p<0·0001, both). Evaluation of 
SYN pathology across increasing levels of AD revealed a step-wise increase in α-synuclein 
stage (p=0·018), cerebral SYN score (p<0·0001), and BG SYN score (p=0·29). There were 
no significant differences between groups for the other neuropathological changes examined 
(Table 1).
Examination of genetic variants previously associated with LBSD11,12,14 (Table 2) revealed 
a decreasing frequency of heterozygous patients carrying the GBA p.E326K risk allele or 
GBA mutation with increasing levels of AD neuropathology (p=0·03, both). SNPs in MAPT 
and SNCA were similar across groups. The frequency of the APOE ε4 allele was not 
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associated with the four levels of increasing AD neuropathology, but in a dichotomous 
comparison of SYN+AD and SYN−AD groups finds patients with one or more copies of 
APOE ε4 were more frequent (p=0.04) in the SYN+AD group (Supplemental Table 1).
Examination of clinical demographics (Table 3) revealed an increasing number of patients 
with a clinical diagnosis of DLB (compared to PDD) with increasing levels of AD 
neuropathology (p<0·0001) (Table 3). Despite the significantly higher frequency of DLB 
clinical phenotype in the SYN+AD group (Supplemental Table 1) there was no clear 
delineation of AD neuropathology groups according to clinical phenotype (Figure 1a). We 
used a ROC curve analysis to test diagnostic accuracy for SYN neocortical stage (Figure 1b; 
AUC=0.67) and SYN+AD (Figure 1c; AUC=0.72) and found poor specificity for both. 
Thus, we did not find evidence of a SYN or AD neuropathological grouping to substantiate 
the MDI 1-year rule, which clinically distinguishes DLB from PDD according to current 
criteria2.
Increasing level of AD neuropathology was associated with older age at motor onset 
(p<0·0001), dementia onset (p=0·005), and death (p=0·001), with significant contrasts 
between AD groups and the no-AD group (Table 3). The time interval from the onset of 
dementia to death was similar between groups. Increasing severity of AD was also 
associated with a stepwise decrement in MDI and survival (Figure 2) which was significant 
between intermediate and high-level AD groups compared with no-AD and low-level AD 
groups (Table 3). We also examined the individual association of Braak (NFT) and CERAD 
(NP) stages with MDI and survival, and found a similar step-wise association of increasing 
CERAD and Braak stages with shorter MDI and survival with more significant differences 
between individual Braak stages than CERAD stages (Figure 2, Supplemental Table 2).
We next examined the correlation of continuous measures (cerebral scores) of individual 
neuropathological changes with demographic features (Figure 3); the cerebral NFT, NP and 
SYN scores were all highly correlated with each other (rho=0·4–0·6, p<0·0001) and 
inversely correlated with the MDI (rho= −0·3– −0·4, p<0·0001) and survival (rho= −0·3– 
−0·4, p<0·0001 all). Cerebral pathology scores did not correlate with age at death.
Univariate linear regression models with MDI as the dependent variable found APOE 
genotype, and continuous measures of cerebral NFT, NP and SYN pathology all had 
significant associations (Supplemental Table 5). Our final multivariate model, controlling for 
age at death, gender and other neuropathological or genetic variables using optimal Bayesian 
Information Criteria found an inverse association with cerebral NFT score (β= −4·0, 95% 
CI=−5·8, −2·6; p<0·0001) and a positive association of age at death (β=0·2, 95%CI=0·02, 
0·3; p=0·05) (Model R2=0·22, p<0·0001) (Supplemental Table 5).
Univariate linear regression models with survival as the independent variable found APOE 
genotype (p=0·003) and continuous measures of cerebral NFT, NP and SYN pathology all 
had significant (p<0·0001) associations (Supplemental Table 6). Our final multivariate 
model found an independent negative association of cerebral NFT score (β= −2·04, 95%CI=
−3·2, −0·8, p=0·003) (Model R2=0·15, p<0·0001) (Supplemental Table 6). Examination of 
interaction terms for cerebral NFT score with cerebral SYN score or with cerebral NP score 
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and for APOE with cerebral NP or cerebral NFT were not significant and did not optimize 
Bayesian Information Criteria values of either model.
Discussion
We performed an analysis of the contribution of AD neuropathology to onset of dementia 
and to survival in LBSD through group-wise comparisons of four levels of AD 
neuropathology severity4. Our retrospective analysis in a large cohort of LBSD patients with 
detailed clinical, pathological, and genetic information found NFT accumulation to be the 
strongest correlate of a shorter MDI and overall survival. We found converging evidence—
using both a continuous measure of cerebral NFT burden score (Figure 3, Table 4) and 
sequential categorical Braak NFT stages (Figure 2, Supplemental Table 2)—which showed 
increasing levels of cerebral NFT burden with worsening of these signs of poor prognosis. 
Indeed, the high-level AD group had on average ~7 years shorter MDI and overall survival 
than the no-AD group (Table 3).
Other studies have also found shorter MDI and overall survival in autopsied PD patients 
with co-morbid AD neuropathology8,18,19 and a similar inverse association of cerebral NFT, 
NP, and SYN pathology with the MDI across LBSD.7 However, additional research has 
reported that Aβ plaques8,20 or a summation of NFT, Aβ, and SYN pathological changes21 
were the strongest correlates of a shorter MDI in LBSD. There are several potential reasons 
for these discrepancies. In our univariate analyses, the cerebral NP score had a significant 
(p<0.0001) inverse association with MDI and survival, but after accounting for NFTs this 
association was not significant (Tables 4,5). Our measure of Aβ accumulation included NPs 
only, rather than all forms of Aβ plaques, which may underrepresent the contribution from 
Aβ. However, our multi-center cohort is one of the largest reported series of clinically-
characterized patients with roughly equal numbers of PDD and DLB patients which allowed 
for comparisons across four levels of Braak/CERAD scores and a continuous measure of 
average cerebral NFT/NP scores. In contrast, previous studies had limited evaluations of 
NFT pathology by collapsing Braak stages for dichotomous comparisons8 or by examining 
categorical Braak NFT stages only20 in smaller samples with relative imbalances of 
PDD/DLB20,21 or only non-demented PD or PDD8. Although in this study we focused on 
LBSD patients who developed dementia (PDD/DLB) and did not examine PD patients who 
came to autopsy prior to the onset of dementia (PDND), we have previously published a 
series of autopsy-confirmed PDND patients6 and found the majority of cases had a low level 
of tau pathology—35/44 (79%) of cases had low Braak tau stages=0–II (i.e. tau pathology 
restricted to the hippocampus only)—which further reinforces our findings here. However, 
our results will need replication in an independent cohort to reconcile these discrepancies.
We also found age at death had an independent association with a longer MDI (Table 4), 
reflecting an overall longer disease course in patients with a long MDI. Thus, age-related 
factors may also contribute to these discrepancies, although in our multivariate regression 
correcting for age at death and sex, we found a significant independent association of NFT 
scores with a shorter MDI (p<0·0001) and survival (p=0·003).
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Although we did not include age at onset in our models because age at death more closely 
reflects the effects of aging on our measures of pathology found at autopsy, it may influence 
clinical phenotype in LBSD. A prospective autopsy study of idiopathic PD (Sydney 
Multicenter PD study)22 found three clinicopathological subtypes defined in-part by age at 
onset, where younger-onset PD patients were more likely to survive longer without dementia 
and have less co-morbid AD neuropathology compared to older-onset PD patients with a 
shorter survival and higher burden of secondary AD neuropathology. This study also found a 
small subgroup of six patients that had typical dopa-responsive PD and early dementia that 
met clinical criteria for DLB with a rapid disease course and high burdens of both SYN and 
AD neuropathology. These clinicopathological subgroups of PD patients are similar to our 
findings here and those previously published for PDND6. While important for providing 
novel insights into the progression of typical idiopathic PD, the Syndey Multicenter PD 
study22 does not include all forms of clinical DLB, many of which do not have typical dopa-
responsive parkinsonism at onset. Indeed, in the current study a subset of individuals 
(n=18/98 DLB, 18%) never developed clinical motor parkinsonism during the course of their 
disease. Similar to the entire DLB cohort, the majority of these non-motor DLB individuals 
had intermediate to high levels of AD neuropathology (16/18, 89%) and neocortical LB 
stage (15/18, 83%).
Thus, this study and our current work provide complementary views of LBSD, and taken 
together, show a complex relationship between aging, SYN, and AD neuropathology. To 
resolve these discrepancies and more clearly define the clinicopathological subtypes of 
LBSD, future studies should quantify neuropathological burden parametrically, and use in 
vivo cerebrospinal fluid or imaging biomarkers of tau, Aβ, and SYN pathology in 
conjunction with detailed clinical data in patients who are prospectively followed to autopsy.
Nonetheless, our present data suggest that the consequences of AD neuropathology, and 
particularly NFT burden, are not solely an artefact of the aging process, but are instead 
central to the pathogenesis of the majority of LBSD patients. Indeed, we found that subjects 
with increasing AD neuropathology also had increasing levels of SYN pathology (Table 1) 
and a strong correlation between cerebral NFT, NP, and SYN scores (Figure 3), which 
suggests a synergistic effect of mixed AD and SYN neuropathology. We and others have 
previously shown associations of higher burden of AD neuropathology with more advanced 
SYN pathology in LBSD;6,8 cerebrospinal fluid markers of tau and SYN pathologies also 
appear to be highly correlated in PD23. These findings echo in vitro evidence for cross-
fibrillization of tau and SYN fibrils24 and conformational strains of pathological SYN that 
co-induce SYN and NFT pathology25. Future research is needed to further elucidate these 
potential mechanisms of co-accelerated pathology.
Other, less common co-morbid pathologic changes may be contributing to dementia in 
LBSD. Approximately 15–20% of our cohort had co-morbid CVD or limbic TDP-43 
pathology, with no clear association with AD neuropathology or with MDI and disease 
duration. The clinical significance of these and other less-common co-morbid pathologies 
(e.g. AGD, HpScl) in our cohort is not certain and we cannot rule out a contribution of these 
pathologies to phenotypic diversity of LBSD on an individual patient level. Future work will 
need to assess these rare, co-morbid pathologies in a larger cohort.
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Another contributing factor to clinical heterogeneity in LBSD emerges from our genetic 
analyses. We found a higher frequency of both GBA mutations and p.E326K polymorphism, 
which both confer risk of LBSD,12,26 in the low-level and no AD neuropathology groups 
(Table 2), and previously found a similar high rate of GBA mutations in LBSD without co-
morbid AD in a cohort of patients with SYN pathology.12 We previously found APOE 
genotype to have an independent effect on the odds of dementia in PD6 and a higher 
frequency of the APOE ε4 allele in LBSD with SYN+AD and SYN−AD pathology both 
compared with controls11. Univariate analyses in this study found that the presence of ≥1 
APOE ε4 allele had an association with a shorter MDI and survival (Supplementary Figure 
1), but these associations were not significant in the final multivariate models which 
included cerebral NFT and NP scores. Further study is needed to elucidate the mechanisms 
causing APOE and GBA polymorphism to impact SYN pathology.
We did not find evidence for a definitive pathological substrate to support the categorical 
clinical distinction between PDD and DLB (Figure 1), despite the findings of higher cortical 
NFT, NP and SYN pathology in DLB compared with PDD (Supplemental Table 3); 
however, neuropathological assessment at autopsy may not accurately identify pathological 
differences that could potentially occur earlier in disease course. Interestingly, we found a 
consistent time interval from dementia onset to death of roughly 5 years across 
neuropathological (Table 3, Supplemental Table 1) and clinical groups (Supplemental Table 
3). Previous studies in PD have shown a poor prognostic association of cognitive impairment 
in PD27,28 with a stereotypical decline to institutionalization and death 3–5 years after the 
onset of dementia29. Thus, the timing of dementia in LBSD is an important prognostic 
factor.
This study has several limitations inherent in a retrospective autopsy investigation. Indeed, 
some patients had missing clinical data; however, we had MDI and survival data for >87% 
of the total cohort. All patients were referred to academic centers specialized in movement 
disorders and/or dementia so there may be a referral bias favoring atypical or more severe 
phenotypes. Replication of our findings in an independent prospective cohort is needed to 
further interpret the generalizability of results; however, we used a bootstrapped random 
patient selection procedure to reduce overfitting of our models. Finally, the 
neuropathological data were collected at autopsy from multiple centers using different 
staining procedures; however, we used standardized methods—used across >30 NIH/NIA-
funded Alzheimer’s centers in the National Alzheimer’s disease Coordinating Center https://
www.alz.washington.edu/ —for merging multi-center data which provide reliability across 
participating institutions to reduce inter-lab variability,4,13 and the neuropathological 
methods and criteria used here were recently validated in a large multi-center study30.
Based on the strong associations of AD neuropathology (more specifically, NFT burden) 
with the time interval between motor symptom and dementia onset, and overall survival 
reported here, we suggest that future clinical diagnostic criteria for LBSD incorporate 
biomarkers for NFT and NP neuropathology for an individualized approach to diagnosis of 
underlying complex molecular pathology in LBSD and to identify patients at greatest risk 
for a more rapid decline. In addition, future clinical trials targeting SYN aggregation and 
propagation may benefit from stratifying analyses based on AD-related biomarker profiles 
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and APOE genotype. Finally, our findings suggest that emerging therapies directed at the 
mitigation of pathological tau and Aβ amyloid could potentially slow the degenerative 
process and onset of cognitive difficulties in the majority of LBSD.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Research in Context
Evidence before this study
We searched PubMed for original research articles from Jan 1, 2006, to April 25, 2016 
using the terms “Lewy body dementia”, “Parkinson’s disease dementia” and “autopsy”. 
We excluded non-autopsied biomarker studies and studies examining SYN pathology 
without clinical LBSD (e.g. co-morbid SYN pathology in clinical AD), since this was not 
the focus of our study. We found three recent studies which specifically addressed the 
neuropathological correlates of the MDI and survival across autopsy-confirmed clinical 
PDD and DLB patients. These studies found a higher deposition of cortical SYN and also 
AD-associated amyloid plaque (NP) pathology in DLB compared with PDD. Further, one 
study found both cortical amyloid plaques and SYN are associated with a shorter MDI 
and survival, while another used decline on a global measure of cognition to determine 
that a summation score of SYN, amyloid-plaque and tau NFT burden was the strongest 
correlate of cognitive decline in LBSD. The third study found similar higher burdens of 
cortical SYN and amyloid NP neuropathology in the short MDI groups (for both DLB 
and PDD patients with MDI 1–9.5 years) compared with PDD with a long MDI (>9.5 
years). One potential reason for these discrepancies between studies relates to sample 
size and relative frequencies of PDD and DLB patients, as each of these studies included 
<55 DLB patients. Another potential source of variability lies within the methodology for 
ascertainment of NFT burden, as two of the studies only used Braak staging as a measure 
of NFTs, which is largely based on topographical spread of pathology and not severity.
Added value of this study
To our knowledge, this is one of the largest multi-center cohorts of autopsy-confirmed 
LBSD patients with detailed clinical, genetic, and neuropathological data to provide a 
systematic examination of the neuroanatomical substrate of the heterogeneity in MDI and 
survival across LBSD. We included four stages of AD neuropathology in LBSD using 
modern neuropathological methods and criteria, and also examined continuous measures 
of AD and SYN pathology (i.e. average cerebral scores). We examined a range of other 
common co-morbid neuropathologic changes in LBSD, together with genetic risk 
polymorphisms for LBSD, to provide a comprehensive assessment of neuropathology in 
LBSD in our final multivariate models. Our outcomes of interest were continuous 
measures of MDI and survival, rather than the categorical clinical classification or non-
specific global measures of cognition used in the studies above. We found that increasing 
severity of the cortical burden of tau NFT pathology is associated with a shorter time 
course to develop dementia and death.
Implications of all the available evidence
The results of this study suggest that biomarkers of AD neuropathology may have 
important prognostic implications for clinical care and clinical trial design in LBSD. 
Current and future AD-targeted disease-modifying therapies may have the potential to 
attenuate cognitive symptoms in the majority of LBSD, as we found that increasing NFT 
severity was associated with decreasing MDI and survival. These observations will 
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require replication in prospective cohorts of living patients using validated biomarkers of 
underlying AD neuropathology.
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Figure 1. Diagnostic accuracy of the “one-year rule” to detect advanced SYN or AD 
neuropathology
A) Distribution of neuropathological AD groups among PDD and DLB clinical phenotypes 
in relation to the one year motor-dementia interval (MDI) rule (dashed line). B) ROC curve 
analysis testing the diagnostic accuracy of the MDI to distinguish neocortical stage of 
synucleinopathy. AUC (0·67, p=0·05), sensitivity of 80%, and specificity of 42% using the 
one-year rule (intersection of dashed lines). C) ROC curve analysis testing the diagnostic 
accuracy of the MDI to distinguish SYN+AD pathology. AUC (0·72, p=0·0004), sensitivity 
of 76%, and specificity of 55% using the one-year rule (intersection of dashed lines).
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Figure 2. Comparison of motor-dementia interval and survival across Lewy body spectrum 
patients stratified by neuropathological group
Box-plots display the range of motor-dementia interval (MDI) for (A) total AD 
neuropathological change, (B) stages of senile plaque pathology, and (C) Braak stages of 
neurofibrillary tau. Dashed lines represent across-groups comparison (one-way ANOVA) 
and solid lines represent post-hoc individual group comparisons (independent t-tests) 
***=p<0·001, **=p<0·01, *=p≤0·05. Kaplan-Meier curves depict the proportion of patients 
surviving at given time points observed for (D) total AD neuropathological change, (E) 
stages of senile plaque pathology, and (F) Braak stages of neurofibrillary tau. Symbols above 
reference line denote: † p≤0·05 compared to int.AD, * p<0·05 compared to low AD/CA/BI-
II, ‡ p<0·02 compared to pure SYN/C0/B0 (independent sample t-tests).
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Figure 3. Comparison of cerebral average neuropathology scores with motor-dementia interval 
and survival in Lewy body spectrum disorders
Scatterplot matrices illustrate individual patient data correlations for each variable row/
column combination for (A) MDI and (B) survival. All cerebral pathologies scores are 
correlated with each other: Cerebral NFT: Cerebral NP (rho= 0·6, p<0·0001), Cerebral NFT: 
Cerebral SYN (rho=0·5, p<0·0001), Cerebral NP: Cerebral SYN (rho=0·4, p<0·0001), 
inversely correlated with MDI: Cerebral NFT: MDI (rho= −0·4, p<0·0001), Cerebral NP: 
MDI (rho= −0·3, p<0·0001), Cerebral SYN: MDI (rho= −0·3, p=0·0001) and survival: 
Cerebral NFT: survival (rho= −0·4, p<0·0001), Cerebral NP (rho= −0·3, p<0·0001) and 
Cerebral SYN: Survival (rho= −0·3, p=0·0001).
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